Schizophrenia Research
Volume 77, Issue 1 , Pages 25-34 , 1 September 2005

Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period

  • Monika Edlinger

      Affiliations

    • Department of Biological Psychiatry, Medical University Innsbruck Anichstraße 35 A-6020, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 512 504 23669; fax: +43 512 504 23628.
    • ,
  • Armand Hausmann

      Affiliations

    • Department of General Psychiatry, Medical University Innsbruck Anichstraße 35 A-6020, Austria
    • ,
  • Georg Kemmler

      Affiliations

    • Department of General Psychiatry, Medical University Innsbruck Anichstraße 35 A-6020, Austria
    • ,
  • Martin Kurz

      Affiliations

    • Department of Biological Psychiatry, Medical University Innsbruck Anichstraße 35 A-6020, Austria
    • ,
  • Ilsemarie Kurzthaler

      Affiliations

    • Department of Biological Psychiatry, Medical University Innsbruck Anichstraße 35 A-6020, Austria
    • ,
  • Thomas Walch

      Affiliations

    • Department of General Psychiatry, Medical University Innsbruck Anichstraße 35 A-6020, Austria
    • ,
  • Michaela Walpoth

      Affiliations

    • Department of General Psychiatry, Medical University Innsbruck Anichstraße 35 A-6020, Austria
    • ,
  • W. Wolfgang Fleischhacker

      Affiliations

    • Department of Biological Psychiatry, Medical University Innsbruck Anichstraße 35 A-6020, Austria

Received 29 December 2004 ,Revised 20 January 2005 ,Accepted 21 January 2005.

References 

  1. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. Expert consensus panel for behavioral emergencies. The expert consensus guideline series. Treatment of behavioral emergencies. Postgrad. Med., May. 2001;1–88(Spec No):89–90(quiz)
  2. American Psychiatric Association . Practice guideline for the treatment of patients with schizophrenia, second edition. Work group on schizophrenia. 2004;http://www.psych.org/psych_pract/treatg/pg/SchizPG-complete-Feb04.pdf
  3. Barnes TRE. Comment on the WHO consensus statement. Br. J. Psychiatry. 1990;156:413–414
  4. Bowers L, Callaghan P, Clark N, Evers C. Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe. Eur. J. Clin. Pharmacol. 2004;60:29–35
  5. Centorrino F, Eakin M, Bahk WM, Kelleher JP, Goren J, Salvatore P, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am. J. Psychiatry. 2002;159:1932–1935
  6. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr. Serv. 2000;51:634–638
  7. Conley RR, Tamminga CA, Kelly DL, Richardson CM. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol. Psychiatry. 1999;46:73–77
  8. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 2004;24(2):192–208
  9. Fleischhacker WW. Clozapine: a comparison with other novel antipsychotics. J. Clin. Psychiatry. 1999;60(Suppl.12):30–34
  10. Fleischhacker WW, Hummer M, Kurz M, Kurzthaler I, Lieberman JA, Pollack S, et al. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J. Clin. Psychiatry. 1994;55(Suppl. B):78–81
  11. Fleischhacker WW, Widschwendter C. Extrapyramidal side-effects: avoidance, diagnosis and treatment. Psychiat. Prax. 2004;31(Suppl. 3):1–6(in press)
  12. Galletly C. Prescribing of psychotropic drugs in an acute inpatient unit. Aust. N.Z. J. Psychiatry. 1999;33(2):281–282
  13. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998–2000. J. Clin. Psychiatry. 2004;65:1377–1388
  14. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch. Gen. Psychiatry. 2001;58:965–972
  15. Katschnig H, Donat H, Fleischhacker WW, Meise U. 4×8 empfehlungen zur behandlung von schizophrenie. Edition pro mente. 2002;
  16. Kiivet RA, Llerena A, Dahl ML, Rootslane L, Sanchez Vega J, Eklundh T, et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br. J. Clin. Pharmacol. 1995;40:467–476
  17. Kissling W. The current unsatisfactory state of relapse prevention in schizophrenic psychoses suggestions for improvement. Clin. Neuropharmacol. 1991;14:33–44
  18. Kurz M, Hausmann A, Honeder M, Kemmler G, Kurzthaler I, Walch T, et al. Veränderungen psychopharmakologischer behandlungsstrategien bei schizophrenie. Neuropsychiatrie. 2003;17:21–28
  19. Kurz M, Hummer M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Efficacy of medium-dose clozapine for treatment-resistant schizophrenia. Am. J. Psychiatry. 1995;152:1690–1691
  20. Lehman AF, Steinwachs DM. Translating research into practice: the schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr. Bull. 1998;24:1–10
  21. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the schizophrenia Patient Outcomes Research Team (PORT) client survey. Schizophr. Bull. 1998;24:11–32
  22. Lehmann AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. The schizophrenia Patient Outcome Research Team (PORT): update treatment recommendations 2003. Schizophr. Bull. 2004;30:193–217
  23. Linden M, Lecrubier Y, Bellantuono C, Benkert O, Kisely S, Simon G. The prescribing of psychotropic drugs by primary care physicians: an international collaborative study. J. Clin. Psychopharmacol. 1999;19:132–140
  24. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr. Bull. 2002;28:5–16
  25. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J. Clin. Psychiatry. 2003;64:9
  26. Meise U, Kurz M, Fleischhacker WW. Antipsychotic maintenance treatment of schizophrenia patients: is there a consensus?. Schizophr. Bull. 1994;20:215–225
  27. Naber D, Hippius H. The European experience with use of clozapine. Hosp. Comm. Psychiatry. 1990;41:886–890
  28. Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for clinical pharmacology. Can. J. Clin. Pharmacol. 1999;6:69–83
  29. NICE clinical guidelines. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. http://www.nice.org.uk/page.aspx?o=42464.
  30. Pollack S, Lieberman JA, Fleischhacker WW, Borenstein M, Safferman AZ, Hummer M, et al. A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effects. Psychopharmacol. Bull. 1995;31:315–320
  31. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can. J. Psychiatry. 2001;46:334–339
  32. Remington GJ, Bezchlibnyk-Butler K. Management of acute antipsychotic-induced extrapyramidal syndromes. CNS Drugs. 1996;5(Suppl. 1):21–35
  33. Remington GJ, Shammi CM, Sethna R, Lawrence R. Antipsychotic dosing patterns for schizophrenia in three treatment settings. Psychiatr. Serv. 2001;52:96–98
  34. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003;290:2693–2702
  35. Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, et al. The usefulness and use of second-generation antipsychotic medications. Suppl. Curr. Opin. Psychiatry. 2002;15(suppl 1):7–16
  36. Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, et al. The usefulness and use of second-generation antipsychotic medications—an update. Suppl. Curr. Opin. Psychiatry. 2003;16(suppl 1):7–17
  37. Stahl MS. Antipsychotic polypharmacy: part 1. Therapeutic option or dirty little secret?. J. Clin. Psychiatry. 1999;60:425–426
  38. Takei N, Inagaki A. Polypharmacy for psychiatric treatments in Japan [letter]. Lancet. 2002;360:649
  39. Tandon R. Safety and tolerability: how do newer generation “atypical” antipsychotics compare?. Psychiatr. Quaterly. 2002;73:297–311
  40. Wang PS, West JC, Tanielian T, Pincus HA. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr. Bull. 2000;26:451–457
  41. Weissman EM. Antipsychotic prescribing practices in the veterans healthcare administration—New York metropolitan region. Schizophr. Bull. 2002;28:31–42
  42. Wilson WH, Ban TA, Guy W. Pharmacotherapy of chronic hospitalized schizophrenics: prescriptive practices. Pharmacopsychiatry. 1985;14:75–82
  43. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am. J. Psychiatry. 1991;148:714–726
  44. World Health Organisation . Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. Br. J. Psychiatry. 1990;156:412

PII: S0920-9964(05)00053-8

doi: 10.1016/j.schres.2005.01.015

Schizophrenia Research
Volume 77, Issue 1 , Pages 25-34 , 1 September 2005

Article Tools

* Image Usage & Resolution